Innate Pharma S.A. Form 6-K Report: Key Investor Insights from February 2025

Here are the key insights extracted from the provided section of the financial report:

1. Document Type: The report is a Form 6-K, which is typically filed by foreign private issuers to disclose information that is material to investors.
2. Date of Report: The report is dated February 17, 2025.
3. Commission File Number: The report references Commission File Number 001-39084, indicating its registration with the SEC.
4. Company Information:

• Name: Innate Pharma S.A.
• Address: 117 Avenue de Luminy, BP 30191, 13009 Marseille, France.
• Contact Number: +33 (0) 4 30 30 30.

5. Filing Status: The company indicates that it files annual reports under Form 20-F, confirming its status as a foreign private issuer.
6. Incorporation by Reference: The report states that it will be incorporated by reference into the registration statements Form F-3 and Form S-8, which is significant for investors as it updates the prospectus information.
7. Exhibit Index:

• The report includes an exhibit, specifically a press release dated February 17, 2025.

8. Signatures: The report has been signed by Jonathan Dickinson, who holds the position of Chairman of the Executive Board and Chief Executive Officer of Innate Pharma S.A.

This summary captures essential details about the nature of the filing, the company involved, and important dates and references that would be relevant for investors or analysts reviewing the company's disclosures.